Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor

Summary

Heparin and low molecular weight heparins (LMWHs) have both antithrombotic and anti-angiogenic activities. The antiangiogenic activity of LMWH may be associated with the release of endothelial tissue factor pathway inhibitor (TFPI), an important endogenous inhibitor of tissue factor/Factor VIIa (TF/fVIIa).To evaluate the effects of LMWH, tinzaparin, and TFPI in a model of angiogenesis-mediated processes, we compared the effects of tinzaparin, and recombinant TFPI in inhibiting either basic fibroblast growth factor-2 (FGF2) or TF/fVIIainduced endothelial cell tube formation in human umbilical vein endothelial cells (HUVEC).Our results show that tinzaparin and recombinant TFPI both blocked endothelial tube formation induced by either FGF2 or TF/fVIIa, in a concentration-dependent manner. Endothelial tube formation was only marginally inhibited by a potent and specific anti-Factor Xa, recombinant tick anticoagulant protein (rTAP). A monoclonal anti-TFPI antibody reversed the inhibitory effects of either tinzaparin or recombinant-TFPI on HUVEC tube formation. Tinzaparin fractions in the range of 8,000 to 12,600 Da were most effective in stimulating the release of TFPI from HUVEC. These results suggest that the inhibitory effect of the LMWH tinzaparin on endothelial tube formation is associated with stimulation of the release of TFPI, but not to anti-Factor Xa activity.

Keywords

Low molecular weight heparin - tinzaparin - endothelial cell tube formation - tissue factor pathway inhibitor

• References

• 1 Felmeden DC, Blann AD, Lip GY. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J 2003; 24: 586-603.
• 2 Mousa SA. Antithrombotics in thrombosis and cancer. Expert Rev Cardiovascular Ther 2003; 01: 283-91.
• 3 Hull RD, Raskob GE, Pineo GF. et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
• 4 Simonneau G, Sors H, Charbonnie B. et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l’Embolie Pulmonaire. N Engl J Med 1997; 337: 663-69.
• 5 Cosgrove RH, Zacharski LR, Racine E. et al. Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost 2002; 28: 79-87.
• 6 von Tempelhoff GF, Harenberg J, Niemann F. et al. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 2000; 16: 815-24.
• 7 Kakkar AK, Williamson RC. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost 1999; 25: 239-43.
• 8 Kohanna FH, Sweeney J, Hussey S. et al. Effect of perioperative low-dose heparin administration on the course of colon cancer. Surgery 1983; 93: 433-8.
• 9 Green D, Hull RD, Brant R. et al. Lower mortality in cancer patients treated with lowmolecular-weight versus standard heparin. Lancet 1992; 339: 1476.
• 10 Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost 2002; 28: 45-52.
• 11 Mousa SA, Fareed J. Overview: from heparin to low molecular weight heparin: beyond anticoagulation. Curr Opin Investig Drugs 2001; 02: 1077-80.
• 12 Mousa SA, Bozarth JM, Barrett JS. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharm Ther 2003; 43: 2-9.
• 13 Norrby K, Ostergaard P. Basic-fibroblastgrowth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcirc Clin Exp 1996; 16: 8-15.
• 14 Norrby K, Ostergaard P. A 5.0-kD heparin fraction systemically suppresses VEGF165-mediated angiogenesis. Int J Microcirc Clin Exp 1997; 17: 314-21.
• 15 Passaniti A, Taylor RM, Pili R. et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992; 67: 519-28.
• 16 Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation and angiogenesis induced by FGF2 or tissue factor/VIIa by low molecular weight heparin or tissue factor pathway inhibitor (TFPI): reversal by anti-TFPI. Blood 2002; 100: 71b.
• 17 American Diagnostica Inc. Greenwich, CT: http://www.americandiagnostica.com/4903%20&%204904.pdf Accessed 6/3/04.
• 18 Hoppensteadt DA, Jeske W, Fareed J. et al. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis 1995; 06: S57-S64.
• 19 Kageshita T, Funasaka Y, Ichihashi M. et al. Differential expression of tissue factor and tissue factor pathway inhibitor in metastatic melanoma lesions. Pigment Cell Res 2002; 15: 212-16.
• 20 Fernandez PM, Rickles FR. Tissue factor and angiogenesis in cancer. Curr Opin Hematol 2002; 09: 401-6.
• 21 Albrecht S, Magdolen V, Herzog U. et al. Soluble tissue factor interferes with angiostatin-mediated inhibition of endothelial cell proliferation by lysine-specific interaction with plasminogen kringle domains. Thromb Haemost 2002; 88: 1054-59.
• 22 Ohta S, Wada H, Nakazaki T. et al. Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer. Anticancer Res 2002; 22: 2991-6.
• 23 Amirkhosravi A, Meyer T, Chang JY. et al. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002; 87: 928-9.
• 24 Amirkhosravi A, Mousa SA, Amaya M. et al. Antimetastatic effect of tinzaparin, a lowmolecular-weight heparin. J Thromb Haemost 2003; 01: 1972-6.
• 25 Lykke J, Nielsen HJ. The role of tissue factor in colorectal cancer. Eur J Surg Oncol 2003; 29: 417-22.
• 26 Rickles FR, Shoji M, Abe K. The role of hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol 2001; 73: 145-50.
• 27 Zhang Y, Deng Y, Luther T. et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94: 1320-7.
• 28 Francis JL, Amirkhosravi A. Effect of antihemostatic agents on experimental tumor dissemination. Semin Thromb Hemost 2002; 28: 29-38.
• 29 Iversen N, Lindahl AK, Abildgaard U. Elevated plasma levels of the factor Xa: TFPI complex in cancer patients. Thromb Res 2002; 105: 33-6.
• 30 Konduri SD, Tasiou A, Chandrasekar N. et al. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2) decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol 2001; 18: 127-31.
• 31 Ribatti D, Vacca A, Dammacco F. et al. Angiogenesis and anti-angiogenesis in hematological malignancies. J Hematother Stem Cell Res 2003; 01: 11-22.
• 32 Hembrough TA, Swartz GM, Papathanassiu A. et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a non-haemostatic mechanism. Cancer Res 2003; 63: 2997-3000.
• 33 Khorana AA, Sahni A, Atland OW. et al. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003; 23: 2110-15.
• 34 Mousa SA, Mohamed S. Anti-angiogenic efficacy and mechanism of the low molecular weight heparin (LMWH), tinzaparin and tissue factor pathway inhibitor (TFPI): potential anti-cancer benefits. Thromb Haemost 2001; Suppl P1982.
• 35 Mousa SA, Bozarth J, Barrett JS. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharmacol 2003; 43: 727-34.
• 36 Bauer KA, Hawkins DW, Peters PC. et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents – the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002; 20: 37-52.
• 37 Walenga JM, Jeske WP, Samama MM. et al. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs 2002; 11: 397-407.